RxDoctor Payments Data

Cynthia Carnie

Optometrist · Hot Springs, ARNPI 1245468743

Payments from drug & device makers

$1,842in general payments, 2019–2025

Across 59 payments — averaging $31.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$738
  • Rxsight Inc$343
  • Bausch & Lomb Americas Inc.$324
  • AbbVie$112
  • Oyster Point Pharma, Inc.$55
  • Eyevance Pharmaceuticals LLC$42
  • plus $229 from 8 others

What the payments were for

  • Food & beverage$1,842100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,842 in reported general payments places this provider in the 80th percentile of 442 optometrist providers in Arkansas.

See all optometrist providers in Arkansas

Medicare billing

Part B allowed, 2024
$193,029
Medicare patients
1,116
Services billed
2,290

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine94$113,698
Cyclosporine22$17,675
LumiganBimatoprost46$16,022
Fluorometholone133$7,878
Latanoprost552$5,529
CombiganBrimonidine Tartrate/Timolol15$4,990
Prednisolone Acetate115$3,274
Travoprost16$2,555
Timolol Maleate182$2,227
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat133$2,000
Brimonidine Tartrate40$1,141
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha59$657
MoxifloxacinMoxifloxacin Hcl21$492
ErythromycinErythromycin Base47$414
Doxycycline Hyclate17$346

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan$112$134,710155 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 442 optometrist providers in Arkansas.

Other optometrist in Hot Springs

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →